None listed
Conditions
Interventions
Intervention1: Meglow Premium Fairness Cream for women and men: All eligible subjects who meet the Inclusion and Exclusion will be enrolled into the study will have to visit the study site on screenin
Sponsors
Leeford Healthcare Limited India
Milagro Clinical Research
Eligibility
Inclusion criteria
Inclusion criteria: 1. Male and female subjects with aged between 18 to 55 years (Both inclusive) 2. Subjects who are willing to give written informed consent 3. Fitzpatrick skin type III & IV 4. Subjects with spots, pigmentation, tanning, fine lines, uneven dull skin
Exclusion criteria
Exclusion criteria: 1.Male and female subjects with aged below 18 and above 55 (Both inclusive) 2.Not willing to give written informed consent 3.Individuals with acne and skin infections all over the face 4.Individuals on treatment with ultraviolet light 5.Wide spread dermatitis or dermatitis on test area 6.Immuno-compromised individual 7.Smoking, alcohol or drug abuse 8.Having received skin treatments for esthetic correction in 6 months prior to the study start date 9.Volunteers using facial products containing hydroquinone, steroids, or other creams to reduce wrinkles on the face or who took vitamin supplements of various kinds within the period of 10.General diseases such as diabetes, endocrine disease, hepatic, renal, cardiac and pulmonary disorders, cancer, neurological diseases, drug allergy and inflammatory or immunosuppressive diseases. 11.Use of anticoagulants and antiplatelet drugs, antihistamines, corticosteroids (both topic and systemic), narcotics, antidepressants, immunosuppressive drugs (a part of hormonal or contraceptive treatment which started >1 year before the study) and, in general, drugs potentially interfering with the results according to the opinion of the investigators. 12.Pregnant or lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objective of the study is to determine the efficacy of Meglow Premium Fairness Cream in lightening the skin colour.Timepoint: 28 days | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Effect on skin fine lines, uneven pigmentation, coarse wrinkling and global assessment of skin texture and by self-assessment. 2. Change in dermal quality of life index over 4-week study period. Timepoint: 28 days | — |
Countries
India
Contacts
Public ContactTrupti Desai
Milagro Clinical Research
Outcome results
None listed